12,13 Separately, EGCG also inhibits the production of IL-6, MMP-1 and MMP-3 from FLS.14,15 Furthermore, administration of EGCG reduces the incidence and severity of arthritis in animal models.14,16,17 Despite such promising properties, the use of EGCG for RA therapy has been hampered by a lack of FLS-targeting ability, which leads to non-specific systemic distribution and insufficient accumulation in inflamed joints.18,19. This evidence concerns the gene IL6 and arthritic joint disease.